A version of this story appeared in STAT’s Health Tech newsletter. Click here to subscribe.
In health care, major drug makers have sought to collaborate with health tech up-and-comers. And on the surface, there’s good reason to think that these partnerships can translate into products that can benefit human health.
But the reality is that the interests of the two parties do not always align.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect